Wall Street brokerages expect that NovaBay Pharmaceuticals, Inc. (NYSE:NBY) will report earnings per share of ($0.12) for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for NovaBay Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.14) and the highest estimate coming in at ($0.10). NovaBay Pharmaceuticals posted earnings per share of ($0.36) in the same quarter last year, which suggests a positive year over year growth rate of 66.7%. The firm is scheduled to report its next quarterly earnings report on Thursday, August 10th.
According to Zacks, analysts expect that NovaBay Pharmaceuticals will report full year earnings of ($0.55) per share for the current year, with EPS estimates ranging from ($0.60) to ($0.49). For the next year, analysts expect that the business will report earnings of ($0.09) per share, with EPS estimates ranging from ($0.15) to ($0.02). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow NovaBay Pharmaceuticals.
Several analysts have issued reports on NBY shares. Roth Capital set a $6.00 price objective on NovaBay Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, June 20th. Zacks Investment Research upgraded NovaBay Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, May 17th. Finally, Maxim Group restated a “hold” rating on shares of NovaBay Pharmaceuticals in a research note on Saturday, May 13th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. NovaBay Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $7.00.
NovaBay Pharmaceuticals (NYSE:NBY) traded down 7.14% during midday trading on Tuesday, hitting $3.90. The company had a trading volume of 403 shares. NovaBay Pharmaceuticals has a one year low of $2.12 and a one year high of $5.29. The company’s 50 day moving average is $3.64 and its 200-day moving average is $3.57. The company’s market cap is $59.71 million.
NovaBay Pharmaceuticals Company Profile
NovaBay Pharmaceuticals, Inc, formerly NovaCal Pharmaceuticals, Inc, is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about NovaBay Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for NovaBay Pharmaceuticals Inc. and related companies.